Tauopathies market entry requires shrewd strategies from pharma companies

Écrit par GlobalData Mardi, 28 Mars 2017 11:55 -

GlobalData»

Pharmaceutical companyes troppingits feffectively icompeterivethe are applications space duraches for strategies

The company's latest report states that, given the vast range of unmet needs lin Direguroslicge rAB

Akiko Fukui, MSc, Healthcare Analyst for GlobalData, explains: "Manufacturers are particularly pursuin

"In addition to targeting multiple indications, another ongoing trend is pursuing multiple compounds in a

A very common strategy in the tauopathies marke Disagnetstices patheter 2, nterrichly/ientckli&eOsin/glecatore

Fukui adds: "The discovery stages of potential tauopathy treatments are commonly conducted by smal